Active	Status	Sponsor type	Region	Phase	Filter
21 Active 1 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

20 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bernick, Charles
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease	Completed	3	804	Canada, US, RoW	Simufilam, PTI-125, Placebo	Cassava Sciences, Inc., Premier Research Group plc	Alzheimer Disease	10/24	10/24
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease	Terminated	3	1027	Europe, Canada, Japan, US, RoW	Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo	Biogen, Biogen Idec Research Limited	Alzheimer's Disease	08/24	08/24
EIP21-NFD-504, NCT05869669: RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies	Active, not recruiting	2	160	Europe, US	Neflamapimod, VX-745, Placebo	EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc	Dementia With Lewy Bodies	08/24	03/25
START, NCT05531656: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease	Recruiting	2	540	US	CT1812, Study Drug Active, Placebo, Matching Placebo	Cognition Therapeutics, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium	Early Alzheimer's Disease	04/27	04/27
REPHRASE, NCT05107882: Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test	Completed	N/A	466	Canada, US		Optina Diagnostics Inc., Eastern Virginia Medical School, The Cleveland Clinic, University of Washington, Sunnybrook Research Institute	Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia	07/24	07/24
Sharma, Sanjiv
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects	Enrolling by invitation	3	285	Europe, Canada, US	Experimental: ALZ-801	Alzheon Inc.	Early Alzheimer's Disease	12/25	01/26
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease	Recruiting	3	1200	Europe, Canada, Japan, US, RoW	Remternetug, LY3372993, Placebo	Eli Lilly and Company	Alzheimer's Disease	04/29	10/30
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease	Active, not recruiting	3	1083	Canada, US, RoW	Simufilam, PTI-125, Placebo	Cassava Sciences, Inc., Premier Research Group plc	Alzheimer Disease	05/25	05/25
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease	Active, not recruiting	3	1667	Japan, US	Remternetug (IV), LY3372993, Remternetug (SC), Placebo	Eli Lilly and Company	Alzheimer's Disease	06/24	03/26
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease	Terminated	3	1027	Europe, Canada, Japan, US, RoW	Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo	Biogen, Biogen Idec Research Limited	Alzheimer's Disease	08/24	08/24
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease	Active, not recruiting	3	17004	Europe, Canada, Japan, US, RoW	Inclisiran sodium 300 mg, Placebo	Novartis Pharmaceuticals	Atherosclerotic Cardiovascular Disease	10/27	10/27
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD	Completed	2/3	320	US	Buntanetap/Posiphen, Posiphen Tartrate, Placebo	Annovis Bio Inc.	Alzheimer Disease	02/24	02/24
NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease	Active, not recruiting	2/3	225	Canada, US	Piromelatine 20 mg, Neu-P11, Placebo	Neurim Pharmaceuticals Ltd., Syneos Health	Alzheimer's Disease	06/25	06/25
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease	Completed	2/3	554	US	ATH-1017, Placebo	Athira Pharma	Alzheimer Disease, Dementia of Alzheimer Type	07/24	07/24
NCT06538116: A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease	Recruiting	2	300	Japan, US	Mevidalen, LY3154207, Placebo	Eli Lilly and Company	Alzheimer Disease	12/25	01/26
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease	Recruiting	2	282	Europe, Canada, US, RoW	GSK4527226, Placebo	GlaxoSmithKline, Alector Inc.	Alzheimer's Disease	12/26	02/29
NCT06151288: Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults	Completed	1/2	1015	US	31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine, PCV20, Prevnar 20™	Vaxcyte, Inc.	Pneumococcal Vaccines	07/24	07/24
NCT06297590: A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease	Recruiting	1	32	Europe, Japan, US	LY3954068, Placebo, Flortaucipir F18	Eli Lilly and Company	Alzheimer Disease	02/27	02/27
NCT06750432: PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)	Recruiting	1	128	US	PMN310, Placebo	ProMis Neurosciences, Inc	Alzheimer Disease, Early Onset	07/26	12/26
Raivio, Minna
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease	Terminated	3	1027	Europe, Canada, Japan, US, RoW	Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo	Biogen, Biogen Idec Research Limited	Alzheimer's Disease	08/24	08/24